Biotech Co. (Symbol)

Pharma Co. (Symbol)

Type/Product Area

Amount

Terms/Details (Month)

I. Modified Agreements

Aurora Biosciences Corp. (ABSC)

Pfizer Inc. (NYSE:PFE)

Expansion of 6/99 technology access agreement for Aurora's genomics platform

ND

Agreement will include additional functionality for the Automated Master Compound Store; Pfizer also exercised option to license GenomeScreen technology for assay development, specifically Aurora's retroviral vectors (3/00)

Aurora Biosciences Corp. (ABSC)

Merck. & Co. Inc. (NYSE:MRK)

Expansion of 12/97 agreement providing access to Aurora's fluorescent assay technologies, ultra-high-throughput screening system (UHTSS) and screen development and screening services

ND

Companies added two amendments to agreement; the first provides for additional assay development and screening by Aurora of a group of G protein-coupled receptors isolated by Merck; the second entails modifications of UHTSS (4/00)

Axonyx Inc. (AXYX)

Ares-Serono (Switzerland)

Exercise of licensing option under 5/99 agreeement covering Axonyx's platform anti-amyloid peptide technology

$22.5

Ares exercised licensing option for the technology, triggering final negotiation for a worldwide exclusive licensing agreement under which Axonyx will receive up to $22.5M, milestones and royalties 95/00)

CeNeS Pharmaceuticals plc (UK; LSE: CEN)

Bioglan Pharma plc (UK)

Expansion of 1/00 collaboration on pain control and drug delivery

$13.74

Bioglan obtains rights to market and distribute Moraxen, a new formulation of morphine in Europe (excluding the UK and Ireland) plus exclusive rights to develop and market selected compounds using CeNeS's DepoCore drug delivery system; CeNeS will obtain an exclusive license from Bioglan to develop a selected compound using one of Bioglan's drug delivery technologies; CeNeS' rights to an opioid product will be extended to include Japan, Australasia and Asia; Bioglan will invest #9M (US$13.74M) in CeNeS equity (4/00)

Chromagen Inc.*

DuPont Pharmaceuticals Co. (NYSE: DD)

Second extension of 5/98 assay development and drug screening agreement

ND

Chromogen will develop assays and screen compounds generated in DuPont's internal drug discovery program (4/00)

Corixa Corp. (CRXA)

Wyeth Lederle Vaccines

Expansion of 3/94 agreement originally signed with Ribi ImmunoChem Research (acquired 10/99 by Corixa) for access to adjuvants

ND

Wyeth gains access to an oil-based formulation of Corixa's MPL adjuvant and adds several infectious disease fields, including HIV, to original supply and license agreements (3/00)

Coulter Pharmaceutical (CLTR)

SmithKline Beecham plc (UK; NYSE:SBH)

Companies amended 12/98 agreement to jointly develop Bexxar, a radiolabeled monoclonal antibody to treat non-Hodgkin's lymphoma

ND

Coulter reacquired rights to Bexxar outside the U.S.; companies also signed co-promotion agreement that will temporarily use Coulter's sales force for the U.S. promotion of two SmithKline oncology products, Hycamtin and Kytril (4/00)

Genome Therapeutics Corp. (GENE)

Schering-Plough Corp. (NYSE: SGP)

Extension of 12/96 human genomics alliance to discover asthma therapeutics

ND

Companies extended $76M agreement through at least 12/01 (5/00)

Hyseq Inc. (HYSQ)

Kirin Brewery Co. Ltd. (Japan)

Expansion and extension of 10/98 agreement to use Hyseq's Gene Discovery platform to target novel genes involved in cell growth regulation from specific cell lines provided by Kirin

ND

Based on favorable results thus far, companies expanded agreement to include potential drug candidates outside the field of cell growth factors; agreement has been extended through 11/00 to allow additional time to finalize product candidates for further development (5/00)

Metabolex Inc.*

Parke-Davis (unit of Warner-Lambert Co.; (NYSE:WLA)

Addition of second collaboration to 1/99 diabetes deal, initially focused on insulin secretion

$50

New collaboration will focus on the use of genomics to discover and develop therapeutics that treat Type II diabetes by counteracting insulin resistance; Metabolex will receive up to $50M through an up-front license fee, an equity investment and milestones; Metabolex will also receive royalties on sales of resulting products; Parke-Davis gains exclusive worldwide rights to products (5/00)

Millennium Pharmaceuticals Inc.(MLNM)

Kyowa Hakko Kogyo Co. Ltd. (Japan)

Extension of 4/97 agreement originally signed with LeukoSite (acquired by Millennium in 1999) to discover and develop new treatments for inflammatory and autoimmune diseases

ND

Agreement extended one year; Millennium receives research funding and milestones, and could receive royalties on any resulting products (3/00)

Molecular Biosystems Inc. (OTC BB MBIO)

Mallinckrodt Inc. (NYSE:MKG)

Restructuring of 4/96 agreement for Optison ultrasound contrast agent

ND

Mallinckrodt gains full control of the Optison business, including responsibility for intellectual property disputes, clinical development, manufacturing and real estate; new deal follows settlement of patent dispute involving Nycomed Amersham plc (UK; NYSE: NYE) and Sonus Pharmaceuticals Inc. (SNURS); MBI will receive an ongoing royalty of 5% on sales by Mallinckrodt and Nycomed in the Mallinckrodt territory (worldwide, excluding Japan, South Korea and Taiwan); in addition MBI will pay $7M to Mallinckrodt as part of intellectual property settlement (5/00)

Neose Technologies Inc. (NTEC)

Bristol-Myers Squibb Co. (NYSE:BMY)

Expansion of 6/98 agreement to develop ganglioside components for two oncologic vaccines under development at BMS (licensed from Progenics Pharmaceuticals [PGNX])

$3.7

Neose will provide additional process development services and received $3.7M to cover the additional services and delivery of GMP materials (5/00)

Paradigm Genetics Inc. (PDGM)

Monsanto Co. (unit of Pharmacia Corp. [NYSE:PHA])

Expanded 11/99 collaboration in functional genomics ics, now including Renessen LLC as an affiliate

ND

Paradigm and Monsanto will work through Renessen LLC (joint venture of Monsanto and Cargill) to perform genetics research aimed at improving the yields of the most valuable components of grains (4/00)

PowderJect Pharmaceuticals plc and PowderJect Vaccines Inc. (UK; LSE:PJP)

Glaxo Wellcome plc (UK; NYSE:GLX)

Glaxo purchased additional DNA vaccine license in an undisclosed disease area using PowderJect's delivery technology under 3/98 agreement (3/00)

$1.75

Glaxo paid $1.75M in new license and option fees and has now exercised five options to purchase licenses for infectious disease prophylactic and therapeutic vaccines (3/00)

Protein Design Labs Inc. (PDLI)

American Home Products Corp. (NYSE:AHP)

Exercise of option under 1999 agreement covering humanization of monoclonal antibodies under PDL's patents

ND

AHP exercised option for non-exclusive license to PDL's antibody humanization patents in order to market Mylotarg (gemtuzumab ozogamicin; FDA-approved cancer drug developed by Celltech Chiroscience plc [UK;NYSE:CLL]) in Japan and other Asian countries; AHP obtained non-exclusive license for the same product in 1999 covering the U.S. and Europe; PDL will receive a signing and licensing fee, and will be entitled to annual maintenance fees and royalties on sales (5/00)

QLT PhotoTherapeutics Inc. (Canada; QLTI)

CIBA Vision (eye care unit of Novartis AG [Switzerland;NYSE:NVS])

Expansion of 2/95 partnership for photodynamic therapies for eye disease that covers Visudyne (verteporfin; FDA-approved) for age-related macular degeneration

ND

Companies agreed to broaden collaboration to actively develop other compounds used either alone or in combination with photodynamic therapy agents to treat diseaseas characterized by neovascularization in the eye; research and development will be conducted and managed jointly, and companies will share equally in costs and revenues; CIBA retains the main responsibility for sales and marketing (4/00)

Sonus Pharmaceuticals Inc. (SNUS)

Abbott Laboratories (NYSE:ABT)

Restructuring of 5/96 agreement for EchoGen ultrasound contrast agent

ND

Abbott is returning U.S. marketing rights and materials related to EchoGen, but will continue manufacturing EchoGen until mid-2002; the move elminates remianing obligations of Sonus to share net profits or up-front license fees with Abbott under 11/99 restructuring of relationship between the companies outside the U.S. (4/00)

Trega Biosciences Inc. (TRGA)

Boehringer Ingelheim International GmbH (Germany)

Expansion of 1/00 agreement for custom synthesis of exclusive solution phase compound libraries

ND

Companies entered a second agreement for custom synthesis; libraries will be delivered to Boehringer with associated information (5/00)

II. Terminated agreements

There were no terminated agreements between biotech and pharmaceutical companies during the time period covered.

Notes:

# The information in the chart does not cover agreements between biotech companies or agricultural agreements.

* Private companies are indicated with an asterisk

ND = Not disclosed, reported and/or available

AMEX = American Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over The Counter Bulletin Board.

No Comments